Merck MRK and AbbVie ABBV are leading pharmaceutical companies with strong portfolios in oncology and immunology. While ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Presently, Merck only markets and sells one other oncology drug exclusively ... or 9% of revenues, diabetes segment that earned $2.3bn, or 4% of revenues, virology segment, $1.8bn, 2% of revenues ...

Merck already has the world’s biggest selling oral treatment for type 2 diabetes, its DPP-4-based drugs Januvia and Janumet, but it is playing catch-up in the SGLT2 market. The monotherapy and ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Rising competitive pressure on the diabetes franchise and persistent ... better analyze how to play Merck stock. Merck boasts more than six blockbuster drugs in its portfolio, with blockbuster ...

Merck, known as Merck, Sharp and Dohme (MSD) outside the US, markets several diabetes drugs, such as Januvia (sitagliptin), and the recently-approved Steglatro (ertugliflozin) as part of a ...

Merck is also seeing weakness in the diabetes franchise and the generic erosion of some drugs. Merck’s shares have lost 23.5% in the past year compared with a decrease of 4.3% for the industry.

There is also anticipation building for MariTide, its experimental obesity drug entering phase 3 trials, which could position the company to enter the GLP-1 weight loss and diabetes market. On the ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...